Targeted compound design can be applicable during compound optimization
- Building strong SAR and SPR
- Enhancing physicochemical properties of compounds (solubility, Log D, pKa)
- Improving pharmacokinetic properties of compounds (absorption, clearance) to obtain most appropriate systemic exposure (either low or high)
- Rationale for solving issues such as CYP interaction, hERG inhibition, blood-brain-barrier crossing, low metabolic stability (clearance), low plasma stability, low lung retention, etc.
- If applicable, designing compounds as locally acting such as soft drugs (f.i. for occular, intestinal, pulmonary, skin deseases)
- Possible advise on inactive excepients which could be used for in vitro and/or in vivo studies